Yaron Naos - 15 Aug 2023 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role: Sr. VP, Operations
Signature: /s/ Eyal Rubin, POA
Issuer symbol: PLX
Transactions as of: 15 Aug 2023
Net transactions value: $0
Form type: 4
Filing time: 17 Aug 2023, 16:30:12 UTC
Previous filing: 09 Sep 2022
Next filing: 24 Sep 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLX	Common Stock	Award		+187,344	+1391%		200,817	15 Aug 2023	By Trust	F1, F2
holding	PLX	Common Stock						7,112	15 Aug 2023	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.
F2	To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

Content

Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.

To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.